| 2023/02/01 22:00:00 | |
|---|---|
| Price | |
| 291.60 USD | |
| Difference | 0.24% (0.70) |
General attributes
| ISIN | US09062X1037 |
| Symbol | BIIB |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 38,130 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 281.27 USD (100) |
| Ask (Ask size) | 292.09 USD (1,500) |
| Open | 289.57 USD |
| High | 293.23 USD |
| Low | 286.13 USD |
| Close (prev. day) | 290.90 USD |
| VWAP | 290.390787 USD |
| Volume (pcs) | 755,494 |
| Trading volume | 219,298,197.15 |
| Number of trades | 19,399 |
| Last size | 116,029 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: BIOGEN IDEC INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/01/30 |
|
Global Equity Ratings |
|
| 2023/01/09 |
|
Global Equity Ratings |
|
| 2022/12/19 |
|
Global Equity Ratings |
|
| 2022/11/28 |
|
Global Equity Ratings |
|
| 2022/11/18 |
|
Global Equity Ratings |
|
| 2023/02/01 22:00:00 | |
|---|---|
| Price | |
| 291.60 USD | |
| Difference | 0.24% (0.70) |
General attributes
| ISIN | US09062X1037 |
| Symbol | BIIB |
| Exchange | Nasdaq |
| Currency | USD |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 38,130 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 281.27 USD (100) |
| Ask (Ask size) | 292.09 USD (1,500) |
| Open | 289.57 USD |
| High | 293.23 USD |
| Low | 286.13 USD |
| Close (prev. day) | 290.90 USD |
| VWAP | 290.390787 USD |
| Volume (pcs) | 755,494 |
| Trading volume | 219,298,197.15 |
| Number of trades | 19,399 |
| Last size | 116,029 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +39.35% | +27.13% | +8.46% |
| Perf (abs.) | +82.34 | +62.23 | +22.75 |
| Beta | 1.06 | 0.91 | 0.84 |
| Volatility | 54.87 | 45.38 | 50.14 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 290.09 USD (735,694) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 283.25 USD (1,045,862) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 272.31 USD (1,511,425) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 233.78 USD (1,222,145) |
| YTD High | date | 295.90 USD (2023/01/27) |
| YTD Low | date | 265.32 USD (2023/01/05) |
| 52 Weeks High | date | 311.88 USD (2022/11/30) |
| 52 Weeks Low | date | 187.16 USD (2022/05/09) |
All listings for BIOGEN IDEC INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| BX Swiss | 2023/01/13 | 18:00 | 266.237 CHF | 0.01 | 1 |
| Berlin | 2023/02/01 | 21:45 | 266.25 EUR | 0.00 | 18 |
| Duesseldorf | 2023/02/01 | 21:01 | 263.80 EUR | 0.00 | 9 |
| Frankfurt | 2023/02/01 | 16:09 | 266.05 EUR | 0.00 | 2 |
| Hamburg | 2023/02/01 | 08:04 | 264.75 EUR | 0.00 | 1 |
| Hanover | 2023/02/02 | 08:06 | 266.05 EUR | 0.00 | 1 |
| London Stock Exchange | 2023/01/19 | 12:59 | 283.47 USD | 3.67 | 1 |
| Munich | 2023/02/01 | 08:00 | 264.85 EUR | 0.00 | 1 |
| Nasdaq | 2023/02/01 | 22:00 | 291.60 USD | 219.30 | 19,399 |
| SIX Swiss Exchange | 2022/09/28 | 17:36 | 222.00 CHF | 0.00 | 1 |
| Stuttgart | 2023/02/01 | 19:41 | 263.75 EUR | 0.00 | 6 |
| Tradegate | 2023/02/02 | 08:00 | 266.75 EUR | 0.01 | 1 |
| Vienna Stock Exchange | 2023/02/01 | 17:32 | 264.10 EUR | 0.00 | 2 |
| Xetra | 2023/02/01 | 17:35 | 263.95 EUR | 0.02 | 4 |
Company Logo
Contact Details
| BIOGEN INC. |
| - - |
| 225 Binney Street - 02142 Cambridge |
| Telefon: 1-617-679-2000 |
| Fax: - |
| E-mail: info@biogen.com |
PDF Downloads
| Company report: BIOGEN IDEC INC. | |
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |
Members of Management Board
| Stelios Papadopoulos | Chairman of Board of Directors |
| Alexander Denner | Member of Board of Directors |
| Eric Rowinsky | Member of Board of Directors |
| Maria Freire | Member of Board of Directors |
| Richard Mulligan | Member of Board of Directors |
| Stephen Sherwin | Member of Board of Directors |
| Caroline Dorsa | Member of Board of Directors |
| Jesus Mantas | Member of Board of Directors |
| William Hawkins | Member of Board of Directors |
| William Jones | Member of Board of Directors |
| Christopher Viehbacher | Chairman of Managing Board |
| Alphonse Galdes | Member of Executive Committee |
| Anabella Villalobos | Member of Executive Committee |
| Ginger Gregory | Member of Executive Committee |
| Jake Elkins | Member of Executive Committee |
| Mahalakshmi Radhakrishnan | Member of Executive Committee |
| Priya Singhal | Member of Executive Committee |
| Rohin Mhatre | Member of Executive Committee |
| Michael Dambach | Member of Executive Committee |
| Michael Hencke | Member of Executive Committee |
| Michael McDonnell | Member of Executive Committee |
| Rachid Izzar | Member of Executive Committee |
| Robert Kilo | Member of Executive Committee |
| Robin Kramer | Member of Executive Committee |
| Susan Alexander | Member of Executive Committee |